Vertical: CNMBase Year: 2025
Market Size (2025)
$221.36M
Projected (2032)
$315.08M
CAGR (2022–2032)
5.2%
Key Players
10+
Market Overview
The Global Beta-Mannanase Market was valued at USD 221.36 Million in 2025 and is projected to reach USD 315.08 Million by 2032, registering a compound annual growth rate (CAGR) of 5.17% over the 2026–2032 forecast period. In absolute terms, the market is expected to add USD 93.72 Million of value between 2025 and 2032. Historically, the market expanded from USD 190.22 Million in 2022 to USD 210.46 Million in 2024, reflecting steady adoption of beta-mannanase as a standard non-starch polysaccharide (NSP) enzyme in compound feed for poultry, swine and other livestock.
Beta-mannanase (endo-1,4-β-D-mannanase, EC 3.2.1.78) hydrolyses β-mannans, a family of NSPs present in soybean meal, palm kernel meal, copra meal, guar meal and other plant-protein ingredients. β-Mannans are recognised as anti-nutritional factors: they raise digesta viscosity, impair nutrient absorption and, critically, can trigger a feed-induced immune response in which the animal's innate immune system expends energy reacting to mannan structures that resemble microbial surfaces. By breaking these molecules down, beta-mannanase allows nutritionists to reduce dietary energy specifications, include lower-cost and higher-fibre ingredients, and support gut health in production systems where in-feed antibiotic growth promoters are restricted or being phased out.
Key Findings
By Livestock: Poultry is the largest segment, accounting for 50.0% of the market in 2025 (USD 110.68 Million). The Others segment (aquaculture, ruminants, companion animals and other species) is the fastest-growing, with a CAGR of 5.76% over 2026–2032.
By Physical Form: Dry formulations dominate with a 75.0% share in 2025 (USD 166.02 Million), while Liquid formulations are the fastest-growing at a CAGR of 5.98%.
By Region: Asia Pacific is the leading region with a 38.0% share in 2025 (USD 84.12 Million). Middle East & Africa is the fastest-growing region, with a CAGR of 6.55%.
By Country: China is the largest country market, valued at USD 37.85 Million in 2025 (17.1% of the global market). India is the fastest-growing country, with a CAGR of 7.15% over 2026–2032.
Absolute growth: Asia Pacific contributes the largest absolute increment between 2025 and 2032 (USD 41.67 Million), followed by North America (USD 16.41 Million) and Europe (USD 15.50 Million).
Segmentation Summary
The study segments the market by livestock and by physical form, with a regional and country-level breakdown. Within livestock, Poultry (USD 110.68 Million in 2025) leads because broiler and layer diets are formulated around soybean meal, the principal dietary source of β-mannans, and because the poultry sector has the highest enzyme inclusion rates of any livestock category. Swine follows at USD 77.48 Million (35.0%), supported by large pig herds in China, the European Union, the United States and Brazil. The Others segment, valued at USD 33.20 Million, is expanding fastest as enzyme use spreads into aquafeed, ruminant and pet food formulations.
By physical form, Dry products (powders and granulates, often coated for pelleting stability) account for USD 166.02 Million in 2025, reflecting their ease of incorporation into premixes and mash or pelleted feeds. Liquid products, valued at USD 55.34 Million, are gaining share as large feed mills install post-pelleting liquid application (PPLA) systems that protect enzyme activity from high conditioning temperatures.
Competitive Landscape Summary
The beta-mannanase market is moderately consolidated at the top and fragmented at the regional level. Elanco Animal Health (Hemicell range) and BASF SE (Natupulse TS) are the leading suppliers of single-activity, EU-authorised beta-mannanase products. AB Vista (Econase MP100), Huvepharma (global distribution of CTCBIO's CTCzyme), CTCBIO Inc., Kemin Industries and Qingdao Vland Biotech Group form a challenger tier, while Advanced Enzyme Technologies, Sunson Industry Group and Novus International serve narrower geographic or product niches. Competition centres on thermostability, dose efficiency, regulatory authorisations, technical service and the ability to bundle mannanase with phytase, xylanase and protease programmes. Ownership change is a notable theme: BASF announced a strategic review of its feed enzyme business in October 2025, and Kemin acquired CJ Youtell Biotech's enzyme and fermentation operations in China in September 2025.
Challenges and Opportunities
Key challenges include volatility in feed ingredient and livestock prices, which compresses producer margins and can delay additive adoption; the cost and duration of feed additive authorisation, particularly in the European Union; price competition from Chinese fermentation-based suppliers; and the variability of β-mannan content across feed ingredients, which complicates the demonstration of consistent returns. Disease events such as African swine fever (ASF) and highly pathogenic avian influenza (HPAI) also create short-term demand disruption in affected countries.
Opportunities arise from the continued phase-out of antibiotic growth promoters, the expansion of commercial poultry production in South and Southeast Asia, Africa and the Middle East, and the increasing use of alternative and by-product ingredients such as palm kernel meal, copra meal and distillers' dried grains with solubles (DDGS). Further opportunities exist in aquaculture and pet food, in liquid formulations for large integrated feed mills, and in concentrated next-generation products that lower inclusion cost per tonne of feed.
Future Outlook
The market is expected to grow from USD 232.83 Million in 2026 to USD 315.08 Million in 2032. Growth will be led by Asia Pacific, which is projected to reach USD 125.78 Million by 2032, and by Latin America and Middle East & Africa, which grow at 5.81% and 6.55%, respectively. Mature markets in North America and Europe will grow more slowly (4.23% and 4.02%) but will remain important for product innovation, regulatory precedent and premium formulations. Over the forecast period, suppliers that combine strong efficacy data, broad authorisations, flexible formats and integrated enzyme programmes are expected to strengthen their positions.
The Beta-Mannanase Market market is projected to grow at a CAGR of 5.2% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Beta-mannanase (endo-1,4-β-D-mannanase; EC 3.2.1.78) is a glycoside hydrolase that randomly cleaves the internal β-1,4-D-mannosidic linkages of mannan-based polysaccharides, including linear mannans, galactomannans, glucomannans and galactoglucomannans. Hydrolysis yields shorter manno-oligosaccharides and reduces the molecular weight and viscosity of the parent polymer. Commercial beta-mannanase is produced by submerged fermentation using bacterial or fungal production strains (for example, Paenibacillus lentus, Bacillus species, Trichoderma reesei, Aspergillus niger and Thermothelomyces thermophilus), followed by recovery, concentration, stabilisation and formulation.
In animal nutrition, beta-mannanase is used as a zootechnical feed additive (digestibility enhancer) to degrade β-mannans present in soybean meal, soybean hulls, palm kernel meal, copra meal, guar meal, sesame meal and similar ingredients. Its benefits include improved feed conversion, energy sparing through reduced feed-induced immune response, improved litter quality in poultry, and greater flexibility in least-cost feed formulation.
Included in the scope of this study:
Feed-grade beta-mannanase products sold for poultry, swine and other livestock (aquaculture, ruminants, companion animals and other species).
Single-activity beta-mannanase products and multi-enzyme preparations in which beta-mannanase is a declared activity, valued at the level of the beta-mannanase product sold.
Dry formulations (powders, granulates, coated and thermostable forms) and liquid formulations (including those applied post-pelleting).
Sales through direct channels to integrators and feed mills, and indirect sales through premix manufacturers and distributors.
Excluded from the scope of this study:
Mannanases sold for household care (laundry and dishwashing detergents), food processing (coffee extraction, juice clarification, baking), pulp and paper, textiles and oil-field applications (guar gum breakers).
Mannan-oligosaccharide (MOS) prebiotics derived from yeast cell walls, which are not enzymes.
Other feed enzymes (phytase, xylanase, β-glucanase, protease, amylase) except where beta-mannanase is a declared activity of the product.
Captive (in-house) enzyme consumption that is not traded.
Scope of the Study
The study quantifies the Global Beta-Mannanase Market in value terms (USD Million) for the historic years 2022–2024, the base year 2025 and the forecast period 2026–2032. Growth rates are expressed as the CAGR for 2026–2032. The market is analysed across the following dimensions, exactly as defined in the study dataset:
Research Objectives
To estimate the size of the global beta-mannanase market in value terms for 2022–2025 and forecast it for 2026–2032.
To analyse market demand by livestock type (Poultry, Swine, Others) and identify the factors driving enzyme adoption in each species.
To assess the relative position and growth of Dry and Liquid beta-mannanase formulations, including the impact of pelleting practices and post-pelleting application.
To quantify regional and country-level demand across North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
To evaluate the drivers, restraints, opportunities and trends shaping the market, including antibiotic growth promoter restrictions, feed cost pressure and alternative ingredient use.
To examine the value chain, competitive forces, PESTEL factors and the regulatory framework governing feed enzymes in major regions.
To identify and benchmark the leading suppliers of beta-mannanase and track their product launches, regulatory approvals, partnerships and acquisitions since 2022.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study follows a structured, multi-stage research process combining secondary research, primary research and analytical modelling. The process began with defining the market scope and segmentation, followed by the collection of secondary data on livestock production, compound feed output, feed enzyme adoption and supplier activity. These inputs were used to build preliminary market estimates, which were then tested and refined through discussions with industry participants across the value chain. The final estimates were validated through data triangulation, and forecasts were developed on the basis of identified drivers, restraints and macroeconomic assumptions.
Stage 1 – Scope definition: market definition, inclusions and exclusions, segmentation and geographic coverage.
Stage 2 – Secondary research: compilation of production, trade, regulatory and corporate data.
Stage 3 – Primary research: interviews with supply-side and demand-side participants.
Stage 4 – Market estimation: top-down and bottom-up modelling, segment and regional allocation.
Stage 5 – Triangulation and validation: reconciliation of estimates from independent approaches.
Stage 6 – Forecasting: projection of market values for 2026–2032 using driver-based models.
Secondary Research
Secondary research provided the foundation for market sizing and qualitative analysis. Sources relevant to the feed enzyme industry included:
Industry associations: feed manufacturer associations and feed additive industry bodies at national and regional level (for example, the American Feed Industry Association, the European Feed Manufacturers' Federation (FEFAC), FEFANA (EU Association of Specialty Feed Ingredients) and the International Feed Industry Federation).
Government and regulatory bodies: agriculture ministries, food and feed safety authorities and statistics offices, including the U.S. Department of Agriculture, the U.S. Food and Drug Administration (Center for Veterinary Medicine), the European Food Safety Authority, the European Commission's EU Register of Feed Additives, China's Ministry of Agriculture and Rural Affairs and India's Department of Animal Husbandry and Dairying.
Intergovernmental statistics: livestock, meat and feed data from FAO (FAOSTAT) and the OECD-FAO Agricultural Outlook.
Company filings: annual reports, investor presentations, product literature and press releases of enzyme manufacturers, animal health companies and feed additive suppliers.
Trade journals and scientific literature: animal nutrition and feed industry publications, EFSA scientific opinions and peer-reviewed studies on beta-mannanase efficacy.
Paid databases: trade statistics, company financial databases and feed industry production surveys.
Primary Research
Primary research was conducted to validate secondary findings, fill data gaps and obtain qualitative insight into market dynamics. Interviews were carried out through telephone, video and e-mail discussions using structured and semi-structured questionnaires.
Supply-side respondents: enzyme manufacturers, feed additive suppliers, premix manufacturers, distributors and technical service managers responsible for product development, sales and regulatory affairs.
Demand-side respondents: nutritionists and procurement managers at integrated poultry and swine producers, commercial compound feed mills, aquafeed producers and livestock consultants.
Objectives: to validate market size and segment splits; understand pricing, inclusion rates and product preferences (dry versus liquid); assess adoption drivers and barriers by species and region; and capture expectations on competitive developments and future demand.
Market Size Estimation
Top-down approach: The global feed enzyme market was used as the starting point and allocated to the beta-mannanase category on the basis of product portfolios, supplier inputs and adoption levels. The resulting value was then distributed across regions, countries, livestock types and physical forms using compound feed production, livestock populations and enzyme penetration indicators.
Bottom-up approach: Country-level demand was estimated by multiplying compound feed volumes for each livestock type by the share of feed treated with beta-mannanase, the typical inclusion rate and the average realised price per unit. Country estimates were aggregated to regional and global totals.
Data triangulation: Estimates from the top-down and bottom-up approaches were compared with supplier revenue indications and primary research inputs. Discrepancies were investigated and reconciled to arrive at final market values, ensuring that segment and regional totals are internally consistent with the overall market total.
Forecasting Methodology
Forecasts for 2026–2032 were developed using a driver-based model that links beta-mannanase demand to underlying livestock and feed fundamentals. Factors considered include:
Projected growth in poultry meat, egg, pork and aquaculture production by country.
Compound feed production trends and the share of soybean meal and other mannan-rich ingredients in diets.
Enzyme penetration rates and the pace of adoption in emerging markets.
Regulatory developments, including restrictions on antibiotic growth promoters and new feed additive authorisations.
Feed ingredient price trends and their effect on demand for energy-sparing additives.
Product innovation (thermostability, concentration, liquid formats) and competitive pricing.
Macroeconomic indicators, including GDP growth, population and per capita protein consumption.
Year-on-year growth rates were applied to the 2025 base year estimates for each country and segment, and the results were reviewed against expert expectations to arrive at the final forecast.
Assumptions and Limitations
Assumptions:
Market values are expressed in nominal USD at average annual exchange rates; future exchange rates are assumed stable at base-year levels.
No major disruption to global feed and livestock supply chains beyond normal cyclical variation is assumed over the forecast period.
Existing feed additive authorisations remain in force, and regulatory trends restricting antibiotic growth promoters continue.
Disease outbreaks such as ASF and HPAI are assumed to have regional and temporary rather than lasting global impacts.
Limitations:
Many suppliers do not report beta-mannanase revenue separately from broader feed enzyme or animal nutrition revenue, requiring estimation.
Multi-enzyme blends that include mannanase activity complicate the attribution of value to beta-mannanase.
Data availability for smaller markets grouped under "Rest of" regions is more limited than for major countries.
Unforeseen regulatory, trade or disease events may cause actual outcomes to differ from forecasts.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The global beta-mannanase market is moderately consolidated at the top and fragmented at the regional level. A small number of companies hold established, EU-authorised single-activity beta-mannanase products backed by extensive efficacy data, while a wider group of regional enzyme manufacturers, particularly in China, South Korea and India, compete on price and local service. Several suppliers also offer mannanase as one activity within multi-enzyme blends.
Competition is based on product efficacy and thermostability, dose efficiency, regulatory authorisations across target markets, availability of dry and liquid formats, and the depth of technical service, including feed analysis, trial support and enzyme matrix values. Because beta-mannanase is typically used alongside phytase, xylanase and protease, suppliers with broad enzyme portfolios can bundle products and compete for a larger share of the customer's enzyme budget. Distribution partnerships are also important: products are often marketed by animal health and feed additive companies that did not develop them, as illustrated by Huvepharma's long-term global supply agreement with CTCBIO for CTCzyme. The competitive landscape is being reshaped by consolidation, with BASF reviewing strategic options for its feed enzyme business from October 2025 and Kemin acquiring CJ Youtell Biotech's enzyme and fermentation operations in China in September 2025.
Key Player Positioning
Based on product portfolio, regulatory footprint, geographic reach and market visibility, the leading companies in the beta-mannanase market can be grouped into three tiers.
Leaders
Elanco Animal Health (U.S.): Elanco markets the Hemicell range (Hemicell HT dry, Hemicell HT-L liquid and the more concentrated Hemicell XT), an endo-1,4-β-D-mannanase produced from Paenibacillus lentus. Hemicell originated at ChemGen Corp, which Lilly agreed to acquire in 2012, and is widely regarded as the benchmark product in the category. Elanco positions Hemicell as an energy-sparing enzyme that reduces the feed-induced immune response to β-mannans. Commission Implementing Regulation (EU) 2023/2645 authorised its mannanase from P. lentus DSM 33618 for poultry and pigs. Elanco reported FY2025 revenue of USD 4,715 million, of which Farm Animal contributed USD 2,362 million, including Poultry at USD 858 million and Swine at USD 379 million.
BASF SE (Germany): BASF launched Natupulse TS, an intrinsically thermostable endo-1,4-β-D-mannanase, in December 2021, in powder and liquid (Natupulse TS L) forms, and offers a higher-concentration version (Natupulse TS 5M). It is produced in Ludwigshafen, where BASF expanded its feed enzyme plant in 2022. Commission Implementing Regulation (EU) 2024/1743 authorised the product for poultry for fattening and ornamental birds. BASF reported FY2025 group sales of EUR 59.7 billion, with its Nutrition & Health division at EUR 1,744 million. In October 2025, BASF announced that it is evaluating strategic options for its feed enzyme business, which may lead to a change in ownership of the Natupulse product line.
Challengers
AB Vista (U.K.; part of AB Agri, Associated British Foods): AB Vista offers Econase MP100, a thermostable preparation with mannanase as its main active, alongside a leading phytase (Quantum Blue) and xylanase (Econase XT) portfolio. The company showcased Econase MP 100 with new China-specific enzyme blends at China Feed Expo in April 2026. AB Vista does not report revenue separately; Associated British Foods reported FY2025 revenue of GBP 19,459 million, with its Agriculture segment at GBP 1,616 million.
Huvepharma (Bulgaria): Huvepharma, a privately held animal health and nutrition company, signed a long-term global supply agreement with CTCBIO for CTCzyme in June 2023, with full-scale supply beginning in 2024. This adds a beta-mannanase to its Hostazym feed enzyme range and gives the product access to Huvepharma's international distribution network. Revenue is not publicly disclosed.
CTCBIO Inc. (South Korea): CTCBIO manufactures CTCzyme, a beta-mannanase feed enzyme that received U.S. FDA approval in 2016 and is exported to major markets, including through Huvepharma. CTCBIO reported FY2025 consolidated revenue of KRW 123.8 billion and returned to operating profit, with export growth driving a sharp increase in operating profit in Q1 2026.
Kemin Industries (U.S.): Kemin offers mannanase within its KEMZYME XPF and KEMZYME XPF Advance multi-enzyme blends for NSP breakdown. In September 2025, Kemin acquired CJ Youtell Biotech, CJ Bio's enzyme and fermentation subsidiary with plants in Shandong and Hunan, China, strengthening its in-house enzyme production. Kemin is privately held and does not disclose revenue.
Qingdao Vland Biotech Group (China): Vland, listed on the Shanghai Stock Exchange, offers a thermostable mannanase within a broad feed enzyme portfolio that includes phytase, xylanase, glucanase and protease. It reported FY2025 revenue of RMB 1,366.12 million. Vland formed a gut-health joint venture with Evonik, which began operating in January 2024, and is expanding overseas through subsidiaries in the United States, Vietnam and Indonesia.
Niche Players
Advanced Enzyme Technologies Ltd (India): The company offers DigeGrain M (powder) and DigeGrain ML (liquid) beta-mannanases for soybean meal, palm kernel meal, rice bran and rapeseed-based diets. It reported FY2026 (year ended March 2026) consolidated revenue of INR 7,458 million, with its Animal Nutrition segment growing 25% to INR 946 million.
Sunson Industry Group (China): Sunson, a Beijing-based enzyme producer with plants in Hebei, Ningxia and Guangdong, offers Nutrizyme beta-mannanase derived from Bacillus lentus for poultry, swine, ruminant, aquaculture and pet applications, and exports to more than 40 countries. Revenue is not publicly disclosed.
Novus International (U.S.): Novus, which markets the CIBENZA enzyme range, acquired BioResource International (BRI) in March 2024, adding BRI's enzyme portfolio, which included a mannanase product, and its enzyme development capabilities. Novus is privately held and does not disclose revenue.
Competitor Dashboard
The dashboard below rates each profiled company on four parameters relevant to competitiveness in the beta-mannanase market. Ratings are qualitative assessments based on publicly available information.
Bargaining Power of Suppliers: Medium
Fermentation inputs such as sugars and nitrogen sources are widely available commodities, limiting the leverage of individual input suppliers.
Specialised inputs, including proprietary production strains, licensed technologies and contract fermentation capacity, are more concentrated and can carry higher bargaining power.
Energy and utility costs affect fermentation economics, and price spikes can be passed on by utility providers.
Bargaining Power of Buyers: High
Large integrators and multinational feed producers purchase significant volumes and run competitive tenders and in-house trials.
Buyers can switch between mannanase suppliers or adjust formulations, as several authorised products are available.
Premixers and distributors aggregate demand and negotiate on price and service.
Threat of New Entrants: Medium
Feed additive authorisation, particularly in the European Union, requires substantial investment and time.
Fermentation capacity and strain development know-how are capital- and knowledge-intensive.
Chinese and Indian fermentation producers with low-cost capacity are entering export markets, increasing the threat in less regulated regions.
Threat of Substitutes: Medium
Multi-enzyme blends, xylanases and β-glucanases partially address NSP-related anti-nutritional effects.
Nutritionists can reformulate diets to reduce mannan-rich ingredients or adjust energy levels instead of using an enzyme.
The specific action of beta-mannanase on β-mannans and the feed-induced immune response limits the scope for direct substitution.
Competitive Rivalry: High
Several global and regional suppliers compete with authorised products, technical service and pricing.
Bundling with phytase, xylanase and protease programmes intensifies competition for share of the feed enzyme budget.
Ongoing consolidation and portfolio reviews are changing competitive positions.
Bargaining power of suppliers: Medium; Commodity fermentation inputs; proprietary strains and capacity are more concentrated.
Bargaining power of buyers: High; Large integrators, tender-based purchasing and several authorised alternatives.
Threat of new entrants: Medium; Regulatory and technical barriers offset by low-cost Asian entrants.
Threat of substitutes: Medium; Other NSP enzymes and reformulation offer partial substitution.
Competitive rivalry: High; Multiple global and regional suppliers, bundling and consolidation.
Market estimates by geography (2032)
InsightAsia Pacific leads with $125.78M by 2032, while Middle East & Africa is projected to grow fastest at a 6.6% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $42.94M | $52.94M | $65.11M | 4.3% | 21% |
| Europe | $43.20M | $52.73M | $64.20M | 4.0% | 20% |
| Asia Pacific | $70.69M | $94.41M | $125.78M | 5.9% | 40% |
| Latin America | $24.26M | $32.23M | $42.73M | 5.8% | 14% |
| Middle East & Africa | $9.14M | $12.57M | $17.26M | 6.6% | 5% |
| Total | $190.22M | $244.88M | $315.08M | 5.2% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$315.08M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Poultry | $160.21M | 5.4% | 51% |
| Swine | $105.72M | 4.5% | 34% |
| Others | $49.15M | 5.8% | 16% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Beta-Mannanase Market covering market dynamics, competitive landscape, and strategic outlook.
The Beta-Mannanase Market market is projected to reach $315.08M by 2032, growing at 5.2% CAGR. The Poultry segment holds the largest share.
The Global Beta-Mannanase Market is shaped by the economics of livestock feeding, the regulatory environment for feed additives and antimicrobials, and the technical progress of enzyme production. Because feed typically represents the largest share of the cost of producing poultry meat, eggs and pork, additives that improve feed efficiency or allow the use of cheaper raw materials attract strong interest from producers. At the same time, adoption depends on demonstrable returns, regulatory approval and technical support. This chapter analyses the growth factors, drivers, restraints, opportunities, trends and challenges affecting the market over 2026–2032.
Market Growth Factor Analysis
The table below summarises five macro and five micro factors influencing the market, together with the direction of their impact and an impact score on a scale of 1 (low) to 10 (high) for three forecast sub-periods. The impact scores are analyst assessments based on secondary research and industry discussions and are intended to indicate the relative strength of each factor over time.
Rising Global Demand for Poultry and Pork
Poultry is the most widely consumed meat globally and continues to gain share from other proteins because of its low cost, short production cycle and absence of major religious restrictions. The OECD-FAO Agricultural Outlook projects continued growth in global meat consumption over the coming decade, with poultry accounting for the largest part of the increase and most of the additional demand arising in Asia, Africa and Latin America. Pork remains the leading meat in China and much of East and Southeast Asia, and herd rebuilding after African swine fever has been accompanied by a shift towards larger, professionally managed farms that use formulated compound feed. Producing one tonne of live weight requires roughly 1.5 to 3 tonnes of compound feed, depending on species and production system, and most of this feed contains soybean meal and therefore β-mannans. The expansion and industrialisation of livestock production directly increases the volume of feed that can be treated with beta-mannanase. This relationship underpins the market's growth from USD 221.36 Million in 2025 to USD 315.08 Million in 2032, with Poultry alone projected to reach USD 160.21 Million by 2032.
Feed Cost Pressure and the Need for Formulation Flexibility
Feed accounts for the majority of the cost of producing broilers, eggs and pigs, so changes in soybean meal and corn prices have a direct impact on producer profitability. The commodity price spike of 2021–2022 and continued volatility since then have encouraged nutritionists to seek additives that lower the cost per tonne of feed without compromising performance. Beta-mannanase supports this objective in two ways. First, by reducing the energy wasted on the feed-induced immune response to β-mannans, it allows a reduction in dietary energy specifications, typically achieved by lowering the inclusion of expensive fats and oils. Second, by breaking down mannans, it enables higher inclusion of lower-cost, mannan-rich by-products such as palm kernel meal, copra meal and soybean hulls. These benefits are particularly relevant in import-dependent markets in Southeast Asia, the Middle East and Africa, where feed ingredient costs are high and exposed to currency fluctuations.
Restrictions on Antibiotic Growth Promoters
Regulatory and market pressure to reduce antimicrobial use in livestock has increased demand for feed additives that support gut health and performance. The European Union banned antibiotics as growth promoters in 2006 and further tightened rules on veterinary antimicrobials through Regulation (EU) 2019/6, which has applied since January 2022. In the United States, the FDA's Guidance for Industry #213 ended the use of medically important antimicrobials for growth promotion from January 2017. China's Ministry of Agriculture and Rural Affairs prohibited growth-promoting antibiotics in feed from July 2020 under Announcement No. 194, and India banned the use of colistin in food-producing animals for growth promotion in 2019. In antibiotic-free and reduced-antibiotic production systems, nutritional strategies that limit intestinal irritation and undigested substrate for pathogenic bacteria become more important. By reducing digesta viscosity and the immune activation associated with β-mannans, beta-mannanase forms part of the nutritional toolkit used to maintain performance without in-feed antibiotics.
Growing Scientific Evidence and Supplier Investment
The body of evidence supporting beta-mannanase has expanded significantly, including peer-reviewed trials in broilers, laying hens, turkeys, pigs and fish, and safety and efficacy assessments by the European Food Safety Authority. Regulatory authorisations such as Commission Implementing Regulation (EU) 2023/2645 for Elanco's mannanase and Commission Implementing Regulation (EU) 2024/1743 for BASF's mannanase have reinforced confidence in the category among European feed producers. Suppliers have also invested in production capacity and product development: BASF expanded its feed enzyme plant in Ludwigshafen in 2022, Elanco introduced the more concentrated Hemicell XT, and Kemin acquired fermentation assets in China in 2025. Wider distribution partnerships, such as Huvepharma's long-term global supply agreement for CTCBIO's CTCzyme, have extended market reach. Together, these investments improve product availability, lower cost per treated tonne and broaden the base of customers using beta-mannanase.
Expansion in Emerging Livestock Markets
Commercial poultry and pig production is expanding rapidly in South and Southeast Asia, Sub-Saharan Africa, the Middle East and parts of Latin America, driven by population growth, urbanisation and rising incomes. Enzyme penetration in many of these markets remains below the levels of North America and Western Europe. India, the fastest-growing country market in this study at a CAGR of 7.15%, and the Middle East & Africa region, growing at 6.55%, illustrate the potential for suppliers that invest in local technical service and distribution.
Aquaculture, Ruminant and Pet Food Applications
Aquafeed manufacturers increasingly replace fishmeal with plant proteins such as soybean meal, which introduces β-mannans into fish and shrimp diets. Beta-mannanase can help improve the digestibility of these diets. Interest is also growing in ruminant and pet food applications. These uses are reflected in the Others segment, which is the fastest-growing livestock segment with a CAGR of 5.76% and is projected to reach USD 49.15 Million by 2032.
Liquid Formats and Next-Generation Products
Large integrated producers and feed mills increasingly use high conditioning temperatures for hygiene and pellet quality, which can damage heat-sensitive enzymes. Liquid beta-mannanase applied after pelleting avoids this issue and allows precise dosing. The Liquid segment is growing at 5.98%, faster than Dry at 4.89%. Continued development of concentrated, intrinsically thermostable products and of combined enzyme programmes offers suppliers opportunities to differentiate and to capture additional value.
Volatile Livestock Margins and Disease Outbreaks
Livestock production is cyclical, and periods of low meat prices or high feed costs reduce producer margins and can lead to cuts in discretionary additive spending. Disease outbreaks add further volatility. African swine fever caused severe losses in China's pig herd from 2018 and has since affected many countries in Asia and Europe, while highly pathogenic avian influenza has led to the culling of large numbers of birds in North America, Europe and Asia in recent years. Such events reduce feed demand in affected regions and can temporarily slow enzyme sales, although herd rebuilding is often accompanied by more professional feeding practices.
Regulatory Cost and Time to Market
Feed enzymes are regulated as feed additives in most major markets, and authorisation requires extensive dossiers covering safety for the target animal, consumer, user and environment, as well as efficacy data. In the European Union, the authorisation process under Regulation (EC) No 1831/2003 involves an EFSA assessment and a Commission implementing regulation, and authorisations must be renewed every ten years. These requirements raise barriers for smaller suppliers and lengthen the time needed to bring new strains and formulations to market. Differences between national regulatory regimes also add cost for companies seeking global approvals.
Variability in Response and Price Competition
The response to beta-mannanase depends on the β-mannan content of the diet, the animal's age and health status, and the presence of other enzymes. This variability can make it difficult for suppliers to demonstrate consistent returns, particularly where diets contain low levels of soybean meal. In addition, the entry of lower-cost suppliers, especially from China, has increased price competition and pressure on margins, which may limit value growth even as volumes increase.
Challenge: Demonstrating Value in Low-Mannan Diets
In regions where diets are based on wheat, barley or corn with moderate soybean meal inclusion, the β-mannan load is lower and the benefit of beta-mannanase may be less pronounced. Suppliers must provide region-specific trial data, feed analysis services and clear return-on-investment calculations to secure adoption in these markets.
Trend: Shift Towards Concentrated and Thermostable Products
Suppliers are introducing higher-activity formulations that lower inclusion rates and logistics costs, as well as intrinsically thermostable enzymes that survive pelleting without coating. Elanco's Hemicell XT, launched in 2022 at a higher concentration than Hemicell HT, and BASF's Natupulse TS 5M are examples of this trend.
Trend: Consolidation and Portfolio Reshaping
The feed enzyme industry is undergoing significant ownership changes. Novonesis acquired dsm-firmenich's share of the Feed Enzyme Alliance in 2025, dsm-firmenich agreed in February 2026 to sell its Animal Nutrition & Health business to CVC Capital Partners, BASF began a strategic review of its feed enzyme business in October 2025, and Kemin acquired CJ Youtell Biotech in September 2025. These moves are likely to reshape supply relationships and competitive positioning in the beta-mannanase segment.
Trend: Integrated Enzyme and Gut-Health Programmes
Nutritionists increasingly evaluate enzymes as part of a combined programme rather than as stand-alone additives. Suppliers are responding with multi-enzyme blends, matrix values that account for interactions between phytase, xylanase, protease and mannanase, and combinations with probiotics and other gut-health solutions.
The beta-mannanase value chain extends from fermentation inputs to livestock producers. Value is concentrated in strain development, fermentation know-how and regulatory authorisations, while formulation, distribution and technical service shape customer relationships.
Raw materials and inputs: Fermentation requires carbon and nitrogen sources, mineral salts and process utilities. Input costs are influenced by agricultural commodity and energy prices but represent a modest share of final product value, given the importance of strain productivity and process efficiency.
Manufacturing: Large-scale fermentation capacity and process know-how are major sources of competitive advantage. Manufacturers formulate the enzyme concentrate into dry products, often granulated and coated to withstand pelleting, or into stabilised liquid products for post-pelleting application.
Distribution and channels: Global suppliers serve large integrators directly and work with premixers and distributors to reach smaller feed mills. Technical service, including feed analysis, trial support and formulation advice, is an important part of the offer.
End users: Integrated poultry and swine producers and commercial feed mills are the principal buyers. Their decisions are driven by cost per tonne of treated feed, demonstrated performance and compatibility with existing enzyme programmes.
Beta-mannanase is regulated as a feed additive or feed ingredient in all major markets. Authorisation requirements determine the speed at which new products can be introduced and influence the competitive position of suppliers.
The table below summarises key product launches, regulatory approvals, acquisitions, partnerships and expansions by companies active in the beta-mannanase market since 2022.
Jan 2022: BASF SE; Expansion; Expanded its feed enzyme production plant in Ludwigshafen, Germany, which produces Natuphos E, Natugrain TS and Natupulse TS.
Sep 2022: Elanco Animal Health; Product launch; Launched Hemicell XT, a more concentrated beta-mannanase, in the U.K.
Feb 2023: Elanco Animal Health; Regulatory; EFSA published its scientific opinion on Hemicell HT/HT-L produced with Paenibacillus lentus DSM 33618 for poultry and pigs.
Feb 2023: AB Vista; Acquisition; Acquired the Progres feed additive from Hankkija (Finland), broadening its gut-health portfolio.
Jun 2023: CTCBIO Inc. / Huvepharma; Partnership; Signed a long-term global supply agreement for the CTCzyme beta-mannanase.
Oct 2023: Qingdao Vland Biotech Group; Partnership; Announced a gut-health joint venture with Evonik, Evonik Vland Biotech (Shandong), which began operating in January 2024.
Nov 2023: Elanco Animal Health; Regulatory approval; Commission Implementing Regulation (EU) 2023/2645 authorised its mannanase preparation for poultry and pigs until December 2033.
Mar 2024: Novus International; Acquisition; Completed the acquisition of BioResource International, an enzyme developer whose portfolio included a mannanase product.
Mar 2024: CTCBIO Inc. / Huvepharma; Partnership; Began full-scale supply of CTCzyme to Huvepharma following feed trials.
Mar 2024: Advanced Enzyme Technologies; Acquisition; Increased its stake in JC Biotech from 89.83% to 95.72%.
Jun 2024: BASF SE; Regulatory approval / launch; Commission Implementing Regulation (EU) 2024/1743 authorised Natupulse TS for poultry for fattening and ornamental birds; the product was subsequently launched in Europe.
Jul 2024: Elanco Animal Health; Divestment; Completed the sale of its aqua business to Merck Animal Health for approximately USD 1.3 billion to focus on core farm animal and pet health businesses.
Sep 2025: Kemin Industries; Acquisition; Acquired CJ Youtell Biotech, CJ Bio's enzyme and fermentation subsidiary with plants in Shandong and Hunan, China.
Oct 2025: BASF SE; Strategic review; Announced it is evaluating strategic options for its feed enzyme business, including the Natupulse TS beta-mannanase.
Apr 2026: AB Vista; Product launch; Introduced new China-specific enzyme blends (Monophyx and Zhutase) and showcased Econase MP 100 at China Feed Expo 2026.
Aug 2026: Advanced Enzyme Technologies; Acquisition; Board approved the acquisition of the remaining 4.28% stake in JC Biotech, making it a wholly owned subsidiary.
Political
Government policies on antimicrobial resistance, including national action plans, are reducing antibiotic use in livestock and supporting alternatives such as feed enzymes.
Trade policies and tariffs affecting soybean, corn and meat trade influence feed formulation and livestock production patterns.
Food security priorities in import-dependent countries, particularly in the Middle East and Asia, encourage domestic poultry production and feed efficiency.
Economic
Feed ingredient price volatility increases interest in additives that reduce feed cost per unit of meat or eggs produced.
Rising incomes in emerging economies drive demand for animal protein and commercial feed.
Currency fluctuations affect the cost of imported enzymes in emerging markets.
Social
Consumer demand for antibiotic-free and responsibly produced meat and eggs encourages non-antibiotic nutritional solutions.
Urbanisation and dietary change increase consumption of poultry and pork.
Growing awareness of animal welfare supports interest in additives that improve gut health and litter quality.
Technological
Protein engineering and strain improvement enhance thermostability, specific activity and fermentation yields.
Post-pelleting liquid application systems and precision dosing technologies support liquid enzyme adoption.
Rapid feed analysis tools (e.g., NIR) allow nutritionists to measure NSP content and tailor enzyme use.
Environmental
Improved feed efficiency reduces the feed required per unit of output, lowering the environmental footprint of livestock production.
Better nutrient digestibility can reduce nutrient excretion and support manure management.
The use of agro-industrial by-products such as palm kernel meal and copra meal supports circular use of resources.
Legal
Feed additive authorisation requirements, including periodic renewals in the European Union, govern market access.
Labelling, good manufacturing practice and feed safety regulations apply to enzyme producers and feed mills.
Intellectual property protection for strains and formulations shapes competitive dynamics.
Profiles of 108 companies operating in the Beta-Mannanase Market market, including revenue, employee count, and market positioning where available.
Showing 108 of 108 companies
BASF is the world's largest chemical company by sales, built on the Verbund principle of physically and energetically integrated production sites that turn a handful of feedstocks into thousands of products. Since September 2024 it has run under the "Winning Ways" strategy, which splits the portfolio into four core segments (Chemicals, Materials, Industrial Solutions, Nutrition & Care) that stay integrated, and standalone businesses (Agricultural Solutions, Battery Materials, Environmental Catalyst and Metal Solutions, and the now-divested Coatings) that are being monetized or prepared for capital-market options. In 2025 it generated €59.7 billion in sales and €6.6 billion in EBITDA before special items, a cyclical trough. In 2026 it closed the €7.7 billion Coatings transaction, started up its €-multi-billion Zhanjiang Verbund site, raised earnings guidance, and approached Evonik about a takeover. The investment debate is whether structural cost cuts and portfolio proceeds can restore returns above the cost of capital. --- **The company's own description.** BASF describes its purpose with the line "we create chemistry for a sustainable future" (BASF news release boilerplate, 2026) and states its ambition to be the preferred chemical company for enabling customers' green transformation. It reports around 108,000 employees, customers in nearly every sector and almost every country, and sales of around €60 billion in 2025. The portfolio is described as four core segments plus standalone businesses bundled in Surface Technologies and Agricultural Solutions. **Independent characterization.** BASF is best understood as three businesses under one roof: 1. **An integrated commodity and intermediates engine** (Chemicals, the Monomers half of Materials). This is a steam-cracker-to-derivatives chain selling ethylene and propylene derivatives, isocyanates, polyamide precursors and intermediates on spread economics. Earnings are driven by feedstock and energy costs, operating rates and regional supply-demand. It is the most capital-intensive part of the group and the main source of the 2023–2025 earnings decline: Chemicals EBITDA before special items fell from €1,342 million in 2024 to €853 million in 2025 (Factsheet FY2025). 2. **Formulated and performance products** (Performance Materials, Industrial Solutions, Nutrition & Care). These sell on specification and performance to automotive, construction, packaging, consumer goods, pharma and nutrition customers. Margins are steadier but have come under pressure from Asian competition and, in Care Chemicals, from consumer trading-down to private-label products (Factsheet FY2025 commentary). 3. **Standalone franchises** with different industry logic: Agricultural Solutions (crop protection, seeds and traits, digital farming), ECMS (emissions catalysts plus precious-metal trading and recycling) and Battery Materials. Agricultural Solutions is the group's highest-margin segment at 21.7% EBITDA margin before special items in FY2025 and the largest single earnings contributor at €2,081 million. **Revenue model.** Revenue is almost entirely product sales under supply contracts and spot transactions. There is no subscription model of consequence; digital farming (xarvio) and licensing of process technology and catalysts are small. Seeds and traits include royalty and licensing income within Agricultural Solutions, not separately disclosed. Precious-metal trading inflates ECMS sales (€7,978 million in FY2025) with pass-through metal value, which is why BASF quotes group margins both including and excluding metals (12.3% excluding metals in FY2025 per the CFO on the February 27, 2026 call, versus 11.0% reported). **Value chain position.** Upstream to midstream in petrochemicals with captive crackers at Ludwigshafen, Antwerp, Port Arthur (joint venture with TotalEnergies), Nanjing (joint venture with Sinopec) and Zhanjiang; midstream to downstream in engineering plastics, polyurethane systems, dispersions, additives, surfactants and vitamins; branded and channel-driven in agriculture. BASF exited upstream oil and gas operations when Wintershall Dea's E&P business was transferred to Harbour Energy in September 2024. **Customers and end-markets.** BASF serves industrial customers in chemicals and plastics, transportation, construction, consumer goods, agriculture, electronics, energy and resources, and health and nutrition. Intersegment transfers are large (Chemicals transferred €3,432 million internally in FY2025 on €10,055 million of third-party sales), which shows how much of the upstream output feeds BASF's own downstream chains.
Company Headquarters: Missouri, US Founded: 1991 Workforce: ~800+ Company Working: Novus International manufactures animal health and nutrition products for livestock, poultry, and aquaculture. The products offered by the company include various preservative premixtures, feed supplements, feed additives, nutritional feed acids, chelated trace minerals, feed preservatives, feed antioxidants, and other specialty ingredients. Under its eubiotics products category, the company offers ACIDOMIX, a uniquely formulated blend of organic acids which ensures delivery of its acidification to the lower digestive tract. In addition to its preserving effects, the product has antimicrobial effects that help reduce bacterial contamination levels and energy waste resulting in optimal growth rates. The company has research & development laboratories and manufacturing facilities in more than 35 countries, as well as offices with field staff in an additional 60 countries. Novus International operates as a subsidiary of Mitsui & Co. (U.S.A.) Inc. and Nippon Soda Co., Ltd.
CTCBIO is a Korean small-cap drug developer and manufacturer with two product groups. The first is animal health: feed enzymes, bacteriophage feed additives, veterinary drugs and, through subsidiary CTCVAC, animal vaccines. The second is human pharmaceuticals: incrementally modified drugs, orally dissolving films, OTC products, probiotics manufactured as OEM/ODM, and distribution of excipients and APIs. Its most distinctive assets are CTCZYME, a fermentation-derived β-mannanase that the company describes as the first in Asia and second in the world, and which received US FDA approval in 2016, and Wonto Tab, approved in Korea in May 2024 as the first clomipramine/sildenafil fixed-dose combination for premature ejaculation. From 2021 to early 2025 the company went through repeated control contests and losses. It came under the control of SD Group's Bionote in October 2025. After liquidating loss-making subsidiaries, it has reported its best margins in years: H1 2026 parent-only operating margin was 14.6%. The investment case now depends on whether those margins hold, export growth, and synergies with Bionote's animal-diagnostics business. --- **What the company does.** CTCBIO develops, manufactures and sells products in three areas it describes as pharmaceuticals, functional food and veterinary medicines. Its corporate philosophy is "CTC = Change, Try, Challenge". Third-party profiles describe its offer as human and animal pharmaceuticals, feed additives and ingredients, and functional food products. They also list pharmaceutical excipients (coating bases, plasticisers, pore formers, diluents, binders, disintegrants, lubricants, solubilisers), topicals, APIs, animal drugs, physiological activators, functional enhancers and disinfectants. (Sources: PharmaCompass company page; Investing.com profile.) **Reporting structure.** Korean press analysis of DART filings splits consolidated revenue into an animal pharmaceuticals group (동물약품군) and a human pharmaceuticals group (인체약품군). Butler's summary of the Q2 2026 report records a single reportable business, "animal and human pharmaceuticals", at 100% of sales. Google Finance shows a split of about 59% animal and 41% human. That split conflicts with the 9M 2025 DART-based figures reported by DailyPharm (animal ₩32.2bn, human ₩59.9bn), so it is treated as unreliable here. **Business model and revenue model.** **Product sales:** These make up almost all revenue: feed additives and veterinary drugs sold to feed mills, integrators, farms and distributors; finished human drugs sold to hospitals, pharmacies and partner pharma companies. **Contract manufacturing / OEM:** Examples: Dongkoo Bio's Gusejung is produced at CTCBIO's Ansan plant under OEM; probiotics and health functional foods are made on an OEM/ODM basis; the company ran a COVID-19 diagnostic-kit CMO in 2020–22. **Licensing and technology fees:** Historically episodic, mostly from film-type ED drug technology transfers. NH Investment expected ₩3–5bn of such fees in H2 2013. No recent licence income has been reported. **Distribution of third-party materials:** CTCBIO promotes BASF's Kollidon excipient range to Korean formulators (Newspim, 21 Sep 2026). In probiotics it is IFF (Danisco)'s official partner (Dealsite, Aug 2025). **Subscription revenue:** none. **Value-chain position.** The company is vertically integrated from formulation R&D (structure modification, salt changes, combination and film formulation, fermentation-derived enzymes, phage isolation, probiotic coating) through GMP manufacturing in Ansan, Hwaseong and Hongcheon to B2B commercialisation. In animal health it sells mainly to feed manufacturers and global feed-additive marketers such as Huvepharma. In human pharma it sells directly to large hospitals and through partners such as Dongkoo Bio. **Customer types and end-markets.** Livestock feed manufacturers (poultry and swine); global animal-health distributors; Korean livestock farms and veterinary distributors; the companion-animal health market (pet probiotics with Cosmax Pet); Korean hospitals (400+ beds for Wonto) and urology clinics through Dongkoo Bio; pharmacies (OTC Seenexin); pharma companies buying excipients and APIs; health functional food brands buying OEM/ODM probiotics. **Independent characterisation.** CTCBIO is a sub-scale, two-legged specialty manufacturer. It has a few proprietary franchises (CTCZYME, phage additives, film formulations, Wonto) on top of a lower-margin trading and generics base. For most of 2016–2024 its economics were eroded by heavy SG&A (₩43.3bn in 2022 and ₩47.6bn in 2023), loss-making subsidiaries, and governance instability; DailyPharm counted operating losses in eight of the ten years to 2025. Since 2025 the business has been reshaped around fewer, higher-margin products, with the parent company now earning most of the group profit. Under Bionote it is being positioned as the treatment-and-nutrition piece of SD Group's "prevention–diagnosis–treatment" animal-health chain (Dealsite, 28 Oct 2025).
3 interactive charts drawn from the Beta-Mannanase Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Beta-Mannanase Market By Physical Form
Global Beta-Mannanase Market By Livestock
Global Beta-Mannanase Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
